What Cytyc does

Cytyc was a developer, manufacturer, and supplier of diagnostic and surgical products and medical imaging systems focused on women's health. Its portfolio spanned the detection, diagnosis, and treatment of conditions across the women's health lifecycle, including cervical cancer screening (notably the ThinPrep cytology platform), minimally invasive gynecological surgery, breast health diagnostics, and related molecular diagnostic and therapeutic technologies. The company served women's healthcare providers — hospitals, clinical laboratories, and physician practices — as its primary customer segment, distributing products through a combination of direct sales and dealer networks.

Pre-Hologic, Cytyc pursued an aggressive inorganic growth strategy, completing at least six disclosed acquisitions between 2001 and 2007: Pro-Duct Health (2001, $167.5M), Digene Corporation (2002, $553.7M), Novacept (2004, $325M), Proxima Therapeutics (2005, $160M), Adeza Biomedical (2007, undisclosed), and Adiana (2007, $215M). These moves broadened Cytyc across molecular diagnostics, gynecological surgical devices, and prenatal diagnostics, transforming it from a single-product cytology company into a diversified women's health platform. In 2007, Cytyc was itself acquired by Hologic, becoming the anchor asset in Hologic's women's health franchise. Today, Cytyc no longer operates as an independent reporting entity; its products, IP, and customer relationships are integrated into Hologic, which sells across 36 countries via direct sales, dealer networks, and the iStore e-commerce platform. Cytyc's pre-acquisition ownership structure, founding investors, and standalone capital structure are not documented in available sources.

Name

Cytyc

Legal name

Cytyc

Website

https://cytyc.com

Company type

Private

Founded year

1987

Operating status

Acquired

Headcount range

5,001–10,000 employees

Short description

Cytyc developed, manufactured, and supplied diagnostic, surgical, and medical imaging products for women's healthcare providers. Acquired by Hologic in 2007; its cytology, diagnostics, and surgical franchises now operate inside Hologic's global women's health platform.

Ownership category

akta.pro rank

Product category

Women's Health Diagnostics

NAICS

Surgical Appliance and Supplies Manufacturing (339113), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Gynecologic Oncology (HLAKAJAD)

akta.pro secondary industries

Mammography & Breast Imaging Systems (HLAHABAF), Gynecology (General Non-Obstetric Care) (HLAKAJAL)

Keywords

• Women's health diagnostics
• Medical imaging systems
• Cytology testing
• Surgical diagnostics products
• Molecular diagnostics devices

Headquarters

HQ city

Marlborough

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Distribution channels2 records

Marketing channels3 records

Core offering

Cytyc was a developer, manufacturer and supplier of diagnostic and surgical products and medical imaging systems for women's health. Its portfolio spanned cytology, molecular diagnostics, breast health, gynecological health and related screening technologies sold primarily to women's healthcare providers and clinical laboratories. Following its 2007 acquisition, the Cytyc product lines were integrated into Hologic's broader women's health diagnostics and imaging portfolio.

Product overview

No product and services information for Cytyc was found in the provided sources. The source material contains information about Hologic (which acquired Cytyc in 2007) and general women's health industry news, but no specific Cytyc-branded products, modules, or service offerings were documented in the scraped content.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• HologiccoreStrategic or Co-development PartnerHologic acquired Cytyc as part of its strategic expansion in women's health diagnostics. Hologic has completed 22 acquisitions totaling $14.16 billion in the women's health sector, making it the most active strategic acquirer with repeat acquisition behavior reinforcing women's health as a priority growth area.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Hologic: Cytyc's parent company and the largest women's health diagnostics incumbent. Hologic now operates Cytyc's ThinPrep, HPV, NovaSure, and breast imaging product lines within its diagnostics and surgical franchises, making it the most directly comparable player across Cytyc's full portfolio.
• Becton Dickinson (BD): BD is a global medical device and diagnostics company with women's health and cervical cancer screening offerings, including molecular diagnostics and collection devices. Comparable to Cytyc as a broad incumbent across diagnostics and surgical instruments.
• Roche Diagnostics: Roche is a global diagnostics leader offering the cobas HPV test and broader cervical cancer screening solutions. It directly competes with Cytyc's ThinPrep/HPV franchise while also serving adjacent IVD markets.
• Carestream Health: Carestream provides medical imaging systems and healthcare IT solutions used across women's health applications. Comparable to the medical imaging portion of Cytyc's product portfolio.
• Philips Healthcare: Philips is a global medical imaging leader offering mammography and women's health imaging systems. Comparable to Cytyc's breast imaging product line as a broad imaging incumbent.
• Abbott Diagnostics: Abbott is a global diagnostics and medical device company with women's health offerings across immunoassays, molecular diagnostics, and point-of-care testing. Comparable to Cytyc as a broad IVD incumbent with women's health exposure.

Direct peers

• Qiagen: Qiagen offers the digene HPV Test and broader molecular diagnostics for women's health screening, directly competing with Cytyc's HPV testing franchise inherited via the Digene acquisition. Both compete in HPV and cervical cancer molecular diagnostics.
• CooperSurgical: CooperSurgical is a women's health medical device company with products in reproductive medicine, gynecology, and fertility, including minimally invasive surgical solutions. Comparable to Cytyc's NovaSure endometrial ablation and surgical women's health portfolio.
• Myriad Genetics: Myriad Genetics provides molecular diagnostic tests for hereditary cancer risk, including breast and gynecologic cancers. It overlaps with Cytyc's women's health diagnostics focus on cancer risk assessment and screening.

Emerging players

• Natera: Natera offers reproductive and women's health genetic testing, including non-invasive prenatal screening and hereditary cancer tests. Comparable to Cytyc's women's health diagnostics franchise, though with a more focused genetic testing orientation.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/HologicJobs

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytyc